TYME
Tyme Technologies, Inc.
Set alert
52-week range unavailable
- Open
- 0.2901
- Prev close
- 0.3107
- Mkt cap
- 53.50M
- Vol
- 2.68M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.285
- High
- 0.315
- Forward P/E
- -1.55
- Beta
- 0.92
- Short ratio
- 1.12
- Inst. own
- 7.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2022
- 50-d avg
- 0.297422
- 200-d avg
- 0.356265
- 1y target
- 0.00
Key statistics
- Market cap
- 53.50M
- Enterprise value
- -23.57M
- Trailing P/E
- 0.00
- Forward P/E
- -1.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.72
- EPS (TTM)
- -0.137
- Beta
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.93M
- Total cash
- 77.11M
- Total debt
- 26.49K
- Return on equity
- -28.36%
- Shares outstanding
- 172.21M
- Short % of float
- 0.59%
- 50-day average
- 0.297422
- 200-day average
- 0.356265
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2022
Expected Aug 9, 2022. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 25, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 11, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 10, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Jun 10, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 4, 2018 | Canaccord Genuity | init | — | Buy |
| Dec 15, 2017 | H.C. Wainwright | init | — | Buy |
| Nov 17, 2017 | Evercore ISI Group | init | — | Outperform |
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tymeinc.com
News
- Nubank Helps Digital Lender Tyme Reach $1.5 Billion Valuation
- Brazilian digital lender Nubank invests $150 million in Tyme Group
- Nubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the Philippines
- Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
- Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
- SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger
- Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
- SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.
- Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
- Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Your note
Sign in to keep a note on TYME — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIEHL JAMES | Officer | Purchase | Feb 14, 2022 | 105,150 |
| CARBERRY DAVID | Director | Purchase | Sep 21, 2021 | 100,000 |
| DEMURJIAN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 6, 2022 | 22,448,800 |
| GALAINI BARBARA | Officer | Purchase | Nov 11, 2021 | 20,000 |
| HOFFMAN STEVEN E | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 21, 2022 | 20,022,600 |
| KORFIN MICHELE ILENE | Chief Operating Officer | Purchase | Jun 13, 2019 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 3.84% | 3,967,720 | 1.23M | Jun 29, 2022 |
| Blackrock Inc. | 1.86% | 1,928,061 | 599.05K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 1.19% | 1,226,721 | 381.14K | Jun 29, 2022 |
| Geode Capital Management, LLC | 0.77% | 800,667 | 248.77K | Jun 29, 2022 |
| Susquehanna International Group, LLP | 0.67% | 694,379 | 215.74K | Mar 30, 2022 |
| Gsa Capital Partners Llp | 0.57% | 585,966 | 182.06K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.32% | 2,397,410 | 744.88K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.37% | 1,414,981 | 439.63K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.48% | 492,882 | 153.14K | Jun 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.25% | 257,620 | 80.04K | Aug 30, 2022 |
| iShares Micro Cap ETF | 0.15% | 155,564 | 48.33K | May 30, 2022 |
| First Trust Dow Jones Select Micro Cap Index (SM) Fund | 0.15% | 153,316 | 47.63K | Jul 30, 2022 |